Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $701.48M
• Dividend Yield: N/A
• Average Volume (3M): 2.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: 29.88%
• EPS Growth: 35.11%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 160,155,000
• 10 Day Avg. Volume: 2,497,161
• 30 Day Avg. Volume: 2,192,140
• PEG Ratio: -0.74
• Price to Book (P/B): -19.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.75
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 1.19
• Enterprise Value/Gross Profit: 5.24
• Enterprise Value/Ebitda: -14.99
• 1Y Price Target: $6.00
• Price Target Upside: 35.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 60 Neutral
• Price Target: $5.00 ▲(13.12%Upside)

Xeris Pharmaceuticals demonstrates strong revenue growth and positive sentiment from recent earnings calls and corporate events. However, challenges with profitability, leverage, and valuation metrics moderate the overall score.

Positive Factors

Analyst Outlook

Analyst reiterates an Outperform rating, reflecting a strong belief in the company's future prospects.

Financial Performance

Xeris delivered strong revenues, representing around 48% year-over-year growth, marking another consecutive quarter of over 20% year-over-year growth.

Revenue and Growth Outlook

Xeris management provided an ambitious longer-term revenue outlook for the commercial portfolio and Recorlev specifically, including $750M total revenue by 2030 and $1B+ for Recorlev alone by 2035.

Negative Factors

Investor Concerns

Some investors might still want more granular details on the roadmap for Recorlev becoming a blockbuster product, which could take some time.

Product Development

Plans to drive broader adoption in endogenous Cushing’s syndrome via sales force expansion and stepwise investments in Recorlev's commercial infrastructure over time were highlighted.

Revenue Guidance

The company has a tighter revenue guidance, which suggests confidence in achieving financial targets.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, including Gvoke. The company's revenue model is based on the commercialization and distribution of its proprietary drug formulations. Xeris leverages partnerships with healthcare providers, distributors, and pharmacies to expand its market reach and increase product adoption. Additionally, Xeris may engage in licensing agreements or collaborations with other pharmaceutical companies to further monetize its technology platform and product pipeline. The company's earnings are influenced by factors such as market demand for its products, pricing strategies, and the effectiveness of its sales and marketing efforts.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals shows significant revenue growth, but faces challenges with profitability and leverage. Positive strides in operational efficiency are noted, yet negative equity and cash flow issues pose risks.

Income Statement

Xeris Pharmaceuticals has shown significant revenue growth, with Total Revenue increasing from $49.59M in 2020 to $222.55M in TTM (Trailing-Twelve-Months). Gross Profit Margin remains strong, but the company is facing challenges with profitability, as evidenced by negative Net Profit Margin and EBIT Margin. The company is improving its EBITDA Margin, indicating better operational efficiency.

Balance Sheet

The company's balance sheet reveals high leverage with a negative Stockholders' Equity and a substantial Debt-to-Equity Ratio, indicating financial risk. Despite growing assets, the negative equity and increasing total liabilities highlight potential solvency concerns. The Equity Ratio reflects this weak equity position.

Cash Flow

Xeris Pharmaceuticals has improved its Free Cash Flow year-over-year, but it remains negative, indicating cash constraints. The Operating Cash Flow to Net Income Ratio suggests operational cash flow struggles. The company must focus on enhancing cash flow generation to support growth and reduce reliance on external financing.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
222.55M	203.07M	163.91M	110.25M	49.59M	49.59M
	Gross Profit
180.25M	166.24M	135.27M	87.61M	36.27M	36.27M
	EBIT
-22.49M	-33.65M	-44.01M	-81.94M	-115.16M	-115.16M
	EBITDA
-8.66M	-11.30M	-23.73M	-69.31M	-113.67M	-80.08M
	Net Income Common Stockholders
-45.08M	-54.84M	-62.26M	-94.66M	-122.72M	-122.72M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
75.55M	71.62M	72.45M	121.97M	121.97M	102.43M
	Total Assets
108.99M	323.06M	322.60M	344.52M	344.52M	304.36M
	Total Debt
58.30M	271.45M	229.19M	198.06M	198.06M	88.07M
	Net Debt
38.79M	199.83M	161.74M	76.09M	76.09M	20.80M
	Total Liabilities
94.55M	352.68M	329.38M	299.33M	299.33M	209.13M
	Stockholders Equity
14.44M	-29.61M	-6.78M	45.19M	45.19M	95.23M
Cash Flow		Free Cash Flow
-27.43M	-37.85M	-49.29M	-103.42M	-103.42M	-96.62M
	Operating Cash Flow
-26.71M	-36.98M	-47.02M	-102.89M	-102.89M	-95.53M
	Investing Cash Flow
24.52M	4.88M	-6.00M	34.46M	34.46M	97.96M
	Financing Cash Flow
-2.16M	36.17M	-1.61M	127.47M	127.47M	27.25M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.42
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Neutral. The current price of 4.42 is below the 20-day moving average (MA) of 4.74, below the 50-day MA of 4.57, and above the 200-day MA of 3.76, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 18.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NRIX	60 Neutral	$975.05M	―	-64.16%	―	-30.25%	-5.92%
XERS	60 Neutral	$701.48M	―	222.83%	―	29.88%	35.11%
ABCL	56 Neutral	$901.42M	―	-15.59%	―	-35.41%	-12.26%
PRAX	54 Neutral	$908.35M	―	-63.56%	―	270.02%	32.69%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
ZYME	53 Neutral	$904.86M	―	-29.80%	―	85.05%	15.96%
XNCR	52 Neutral	$677.55M	―	-33.48%	―	-25.88%	-29.16%

Xeris Pharmaceuticals Corporate Events

Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Xeris Biopharma Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Three individuals were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved the compensation of the Company’s Named Executive Officers on a non-binding advisory basis.

The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.

Xeris Pharmaceuticals Hosts Analyst and Investor Day

Xeris Pharmaceuticals announced its first Analyst and Investor Day scheduled for June 3, 2025, in New York City, where senior management will discuss the company’s growth strategy and financial outlook. The event aims to highlight the potential of products like Recorlev® and XP-8121, emphasizing their expected impact on revenue growth and the treatment landscape for conditions such as hypothyroidism, potentially affecting stakeholders by demonstrating the company’s commitment to long-term value creation.

The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.

Xeris Pharmaceuticals Announces Board Changes with New Appointment

On March 28, 2025, Xeris Biopharma Holdings announced significant changes to its board of directors. Ricki Fairley resigned due to other commitments, and John Schmid decided not to seek re-election at the 2025 Annual Meeting, leading to a reduction in board size to eight members. James Brady was appointed as a new director, bringing extensive experience from his previous roles at AstraZeneca, including as CFO of MedImmune. His appointment is expected to enhance the board’s expertise as Xeris continues to innovate and expand its market presence.